---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-23-027947"
form_type: "8-K"
ticker: "BVS"
cik: "0001665988"
company_name: "Bioventus Inc."
filed_at: "2023-08-08T23:59:59+00:00"
generated_at: "2026-06-12T02:14:55.400225+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Bioventus Q2 2023 net sales $137.1M (-2.3% YoY); Adjusted EBITDA $28.2M (+26%); FY2023 guidance issued

## Summary
- Net loss from continuing ops $4.7M ($0.06 EPS loss) vs $7.7M loss in Q2 2022, improved.
- Adjusted EBITDA $28.2M, up 26.1% YoY; Non-GAAP EPS $0.14 vs $0.10.
- FY2023 guidance: net sales $490-505M, adjusted EBITDA $75-80M, Non-GAAP EPS ($0.24)-($0.20).
- Repaid $60.3M of term loan and revolver; net leverage ratio reduced to 4.33 from 5.50.
- Closed sale of Wound Business for $31M in net proceeds, used to repay debt.

## SEC filing metadata
- accession: 0001628280-23-027947
- form_type: 8-K
- ticker: BVS
- cik: 0001665988
- company_name: Bioventus Inc.
- filed_at: 2023-08-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1665988/000162828023027947/0001628280-23-027947-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1665988/000162828023027947/bvs-20230808.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-23-027947
- JSON: https://secwatch.observer/filing/0001628280-23-027947.json
- Plain text: https://secwatch.observer/filing/0001628280-23-027947.txt

## Key facts
- Earnings Releases
  Bioventus Inc. reported twelve months ending December 31, 2023 results: revenue $490 million to $505 million, EPS ($0.24) to ($0.20). Guidance initiated.
  - Period: twelve months ending December 31, 2023
  - Revenue: $490 million to $505 million
  - EPS: ($0.24) to ($0.20)
  - Guidance: initiated
  - Result: guidance update
  source text: For the twelve months ending December 31, 2023, the Company expects: • Net sales of $490 million to $505 million • Adjusted EBITDA* of $75 million to $80 million • Non-GAAP EPS* of ($0.24) to ($0.20)
  evidence_url: https://www.sec.gov/Archives/edgar/data/1665988/000162828023027947/0001628280-23-027947-index.htm
- Earnings Releases
  Bioventus Inc. reported three and six months ended July 1, 2023 results: revenue $137.1 million, net income $4.7 million, EPS $0.06. Guidance initiated.
  - Period: three and six months ended July 1, 2023
  - Revenue: $137.1 million
  - Net income: $4.7 million
  - EPS: $0.06
  - Guidance: initiated
  - Result: reported results
  source text: a global leader in innovations for active healing, today reported financial results for the three and six months ended July 1, 2023. Q2 Financial Summary: • Net Sales of $137.1 million, down $3.3 million, or 2.3%, year-over-year as reported (2.3% constant currency*), excluding revenues from divested assets, underlying organic sales decreased $0.5 million, or
  evidence_url: https://www.sec.gov/Archives/edgar/data/1665988/000162828023027947/0001628280-23-027947-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.